DOI · e01.org

Observation of giant cell arteritis patients treated with tocilizumab in a single centre – the Munich GCA patient cohort

Antoine Murray, Lutz, Friederike, Alla Skapenko, Schulze-Koops, Hendrik · German Medical Science (German Research Foundation) · 2019

  • DOI 10.3205/19dgrh257
  • Publisher German Heart Research Foundation
  • Type article
  • Issued 2019

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

German Medical Science (German Research Foundation) · German Heart Research Foundation · article · 2019

Abstract

Background: Tocilizumab (TCZ) subcutaneously (SC) administered has been licensed in Germany since 2017 following the results of the GiACTA study for the treatment of giant cell arteritis (GCA) and thus is an alternative therapy option to long-term glucocorticoids (GC) and other immunosuppressive treatments.[for full text, please go to the a.m. URL]

Open the resolved locator · 10.3205/19dgrh257

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-19 20:00 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
http://doi.org/10.3205/19dgrh257
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.